The UK has cemented its reputation as a global leader in Advanced Therapeutic Medicinal Products (ATMPs), including cell, gene, and oligonucleotide therapies. This high-growth segment requires specialized clinical investigation expertise and robust regulatory pathways, making it a strategic area of focus within the drug development ecosystem. Government and industry investment is heavily...